Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28322641 | 0.89 | TP53 (0.31) | TP53CYP2A6TRPA1 | |
| SCHEMBL16950734 | 0.87 | CNR1 (0.34) | CA2TAAR1 | |
| SCHEMBL16951566 | 0.87 | ACHE (0.33) | TRPA1RXRARXRB | |
| SCHEMBL27382003 | 0.87 | TAAR1 (0.34) | CA2NOS3NOS1NOS2TAAR1 | |
| SCHEMBL457653 | 0.84 | — | — | |
| SCHEMBL455591 | 0.84 | — | — | |
| SCHEMBL16961331 | 0.83 | HPGD (0.41) | PTGS2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL16958042 | 0.83 | GABRA1 (0.34) | NPC1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL16961843 | 0.82 | — | — | |
| SCHEMBL458902 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 964 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344695-A | Hydroxyl-enriched cycloolefin copolymer long afterglow material and application thereof | 重庆理工大学 | 2024-07-16 | — | — | CN | claimed |
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | claimed |
| EP-4355795-A1 | ETHYLENE-ALPHA-OLEFIN COPOLYMER AND PROCESS FOR MANUFACTURING THEREOF | SABIC Global Technologies B.V. (NL) | 2024-04-24 | — | — | EP | claimed |
| WO-2024037146-A1 | ELECTROLYTE SOLUTION AND BATTERY | 珠海冠宇电池股份有限公司 | 2024-02-22 | — | — | WO | claimed |
| CN-117561284-A | Ethylene-alpha-olefin copolymer and process for producing the same | SABIC环球技术有限责任公司 | 2024-02-13 | — | — | CN | claimed |
| CN-117551134-A | Complex and preparation method and application thereof | 南京佳诺霖光电科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| WO-2024022413-A1 | DIVALENT METAL COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ORGANIC OPTOELECTRONIC DEVICE | 中国石油化工股份有限公司 | 2024-02-01 | — | — | WO | claimed |
| CN-117466944-A | Divalent metal complex, preparation method and application thereof, and organic photoelectric device | 中国石油化工股份有限公司 | 2024-01-30 | — | — | CN | claimed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | claimed |
| CN-116574136-A | Bivalent platinum complex and preparation method and application thereof | 南京佳诺霖光电科技有限公司 | 2023-08-11 | — | — | CN | claimed |
| WO-2000003803-A1 | CATALYST COMPOSITION | BP CHEMICALS LIMITED (GB) | 2000-01-27 | — | — | WO | claimed |
| US-5767277-A | REDUCING AGENT FOR A CARBONYL COMPOUND TO PRODUCE A 1,3-SYN-DIOL COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| EP-0810864-A4 | 2,6-DIARYL PYRIDAZINONES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO INC (US) | 1998-03-04 | — | — | EP | claimed |
| EP-0536896-B1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | claimed |
| EP-0810864-A1 | 2,6-DIARYL PYRIDAZINONES WITH IMMUNOSUPPRESSANT ACTIVITY | Merck & Co., Inc. (US) | 1997-12-10 | — | — | EP | claimed |
| US-5663348-A | REDUCTION OF DIKETONE WITH AMINOALKOXYBORANE COMPLEX TO FORM DIALCOHOL ESTER COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1997-09-02 | — | — | US | claimed |
| EP-0669315-A1 | Ortho substituted phenylacetic acid amides | BASF AKTIENGESELLSCHAFT (DE) | 1995-08-30 | — | — | EP | claimed |
| US-5247076-A | IMIDAZOLIDYL MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1993-09-21 | — | — | US | claimed |
| EP-0536896-A1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO. INC. (US) | 1993-04-14 | — | — | EP | claimed |
| WO-1993005059-A1 | IMIDAZOLIDYL MACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | TP53 2915/4885CYP2A6 3645/4885TRPA1 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.